Apremilast in Japanese Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Phase 3, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoint: Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at 16 weeks. Started Jan 2023; status: completed.